Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gem nuclear organelle associated protein 8 (GEMIN8)
- Target
- GEMIN8
- Molecular classification
- Other (integral component of the survival motor neuron (SMN) complex; not a classical receptor, enzyme, transporter, or transcription factor)
01
Overview
Gem nuclear organelle associated protein 8 (GEMIN8) is an integral *and evolutionarily conserved* component of the survival motor neuron (SMN) complex, essential for the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs) and pre-mRNA splicing[1][3][5][7]. It binds directly to SMN1 and the Gemin6/Gemin7 heterodimer, functioning as a central organizer of the SMN complex, ensuring the proper recruitment and delivery of Sm proteins to snRNAs during snRNP assembly[1][2][5]. GEMIN8 is found both in the cytoplasm and localized nuclear subdomains (Gems; Cajal bodies)[3][5]. Altered expression or distribution of GEMIN8 is implicated in neurodegenerative conditions such as spinal muscular atrophy, due to its role in spliceosome integrity[1][4]. No drugs are known to directly target GEMIN8, but modulation of the SMN complex at large is a therapeutic strategy for relevant motor neuron diseases[1][4][5].
- Other names
- Gemin-8FAM51A1Gem-associated protein 8Protein FAM51A1FLJ20514family with sequence similarity 51 member A1
02
Mechanism of action
Not applicable for GEMIN8 specifically, as direct targeting strategies are not established; mechanisms targeting the SMN complex mainly aim to restore snRNP biogenesis
03
Biological functions
snRNP assembly (small nuclear ribonucleoprotein assembly)pre-mRNA splicingorganization of the SMN complex and protein-protein interactions within itmodulation of regulatory interactions (e.g., interaction with protein phosphatase PP1γ)
04
Disease associations
Motor neuron diseases (notably spinal muscular atrophy)Possibly implicated in other disorders affecting pre-mRNA splicing and motor neuron integrity
05
Safety considerations
No specific safety concerns documented for GEMIN8-modulating interventions; typical challenges involve off-target effects when modulating spliceosome or RNA biology
06
Interacting drugs
No drugs are currently reported to directly target GEMIN8; therapeutic strategies in spinal muscular atrophy focus on SMN1 or the SMN complex as a whole
07
Biomarkers
Variations in GEMIN8 expression or localization may serve as a biomarker for motor neuron disease severity or progression, but these are not clinically validated
Beyond the preview
Go deeper on Gem nuclear organelle associated protein 8 (GEMIN8).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gem nuclear organelle associated protein 8 (GEMIN8).